For Corporate Acquirers
Prevent post-close surprises by assessing clinical adoption, manufacturing feasibility, and reimbursement durability before you commit.
The clinical and technical risks that destroy value after close
These aren't financial failures — they're clinical and technical failures. Physicians won't adopt if workflow doesn't integrate. Manufacturing can't scale without supply chain fixes. Reimbursement codes don't transfer across healthcare systems. Vantage identifies these specific risks that destroy acquisition value before you close.
What your M&A advisors structurally can't assess
Financial modeling, legal due diligence, regulatory filings, and strategic fit. They're excellent at what they do.
We work alongside your existing advisors — adding the clinical-technical layer that financial due diligence structurally can't. Most acquisitions use both: Standard advisory for financial and legal, Vantage for clinical and technical.
Vantage never takes equity positions, doesn't advise target companies, and maintains strict independence from your transaction advisors. Our sole obligation is identifying material risks your internal team might miss. We're paid to be objective — not to support a deal thesis.
We never advise competing bidders on the same target. Engagement-level NDA with explicit non-compete provisions ensures your diligence intelligence remains exclusively yours throughout the deal process and beyond.
Clinical-technical DD plugs into your existing deal workflow
How Vantage expands your due diligence coverage
Your financial and legal advisors handle their domains. These are the clinical-technical risks they can't evaluate.
Physician workflow integration, KOL sentiment, clinical evidence gaps
Supply chain risk, scale-up readiness, integration compatibility
Predicate strategy, pathway timeline, post-market requirements
CPT pathway, coverage probability, coding transfer risk
Our Services
Clinical adoption validation for corporate buyers.
We don't replace your financial, legal, or regulatory counsel. Vantage adds the clinical-technical layer they structurally can't provide — physician adoption analysis, manufacturing integration assessment, and clinical workflow validation. Your existing advisors keep doing what they do well. We cover the gap that causes post-close integration surprises.
Most corporate acquirers start with Acquisition DD for active targets or Target Screening to evaluate pipeline. Both are designed to fit standard M&A timelines and deliver board-ready intelligence without disrupting your process.
15 business days
proprietary assessment covering clinical adoption, manufacturing integration, reimbursement validation, and portfolio fit.
7-10 business days
Rapid commercial viability assessment for acquisition targets in your pipeline. Prioritize which opportunities warrant full diligence investment.
Comprehensive assessment
Extended assessment with competitive intelligence, market validation, adoption modeling, and 90-day integration roadmap.
Annual partnership
Ongoing strategic advisory with target screening, priority scheduling, quarterly market intelligence, and SME consultation access.
Our Guarantee: If our assessment doesn't identify at least one material risk — clinical, regulatory, engineering, or commercial — that your existing diligence process overlooked, we refund the engagement in full.
Board-ready deliverables for strategic acquisition decisions.
Our reimbursement analysis covers CPT/HCPCS code pathway viability, Medicare coverage determination probability, commercial payer landscape mapping, ASP and reimbursement rate sustainability, and coding transfer risk during ownership changes. This matters because a device with FDA clearance but no viable reimbursement pathway has significantly diminished commercial value.
Identifying clinical and manufacturing risks before close costs a fraction of post-close remediation and protects deal value.
Typical remediation cost when clinical integration, manufacturing, or regulatory risks emerge post-acquisition
Pre-close assessment identifies the same risks, giving you leverage to adjust terms or structure risk mitigation
Risk-adjusted ROI when material clinical or manufacturing risks are identified and addressed pre-close
Example: A clinical adoption barrier identified pre-close allows structuring a $1.5M physician training and workflow integration program into deal terms. The same barrier discovered 12 months post-close typically requires $8-12M in product redesign, clinical re-validation, and delayed revenue realization.
Deliverables designed to go straight into your board package
Every assessment concludes with a board-ready summary including Vantage Score, material risk findings, and a clear proceed/caution/pass recommendation.
Standard M&A advisory handles financial and legal. Vantage adds clinical-technical intelligence.
| Capability | Standard M&A Advisory | Vantage Clinical-Technical DD |
|---|---|---|
| FDA Pathway Analysis | General regulatory overview | Deep predicate strategy, clinical evidence gap analysis, CDRH submission readiness |
| Clinical Adoption Risk | Not typically covered | Physician workflow analysis, adoption barrier mapping, KOL sentiment |
| Time to Deliver | 8–12 weeks | 2–4 weeks |
| Team Background | MBA/Finance consultants | MD + BME with clinical and engineering experience |
| Manufacturing Risk | Financial audit of COGS | Quality system assessment, supplier risk, scale-up feasibility |
| Reimbursement Analysis | Market size TAM/SAM | CPT code pathway, payer coverage probability, ASP analysis |
| Post-Close Support | Project ends at report delivery | 90-day integration checkpoint, ongoing advisory available |
| Cost Range | $150K–$400K+ | $42K–$185K |
| Board-Ready Output | Generic consulting deck | Structured risk scorecard designed for board governance |
We stay engaged through the most critical integration period
Practicing physician and Medical Director at Adventist Health White Memorial. Chairs P&T Committee evaluating device adoption for 150+ physicians. Brings the clinical adoption perspective that financial DD structurally can't provide.
BS Biomedical Engineering, UC Irvine; MSE Quality, Reliability & Statistical Engineering, ASU. Part of the Axonics operations engineering team that navigated the regulatory and manufacturing path leading to Boston Scientific's $4.1B acquisition.
How It Works
Your assessment moves through six integrated stages — each combining physician expertise with engineering rigor.
Insights for Strategic Acquirers
Intelligence for corporate M&A leaders
Why clinical adoption assessment belongs in your standard M&A diligence workflow.
ReadHow manufacturing integration risk often derails post-acquisition value realization.
ReadNavigating reimbursement pressure, regulatory shifts, and integration complexity in the current market.
ReadSchedule a consultation to discuss your M&A pipeline.
Schedule a Discovery CallIn 20 minutes, we'll identify the 3 biggest clinical and integration risks for your target — no charge, no obligation.
1-3 Internal findings from analysis of documented medical device acquisition patterns across portfolio companies. 4 96% historical accuracy — Retrospective validation of Vantage scoring framework against documented medical device outcomes across 100+ companies. 5 Proximo Medical; MDDI Online. 6 "What's Driving Successful M&A? Insights from 70-90% of deals failing to create expected value" — Harvard Business Review (Roger L. Martin, 2016). 7 McKinsey & Company analysis of 2,500+ transactions: 61% of deals do not earn back cost of capital. 8 MedDevice Online; Academic Entrepreneurship for Medical and Health Sciences — average regulatory timeline from FDA clearance to CMS reimbursement code assignment.